Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 7, n. 6, p. s291, 2023. DOI: 10.25251/skin.7.supp.291. Disponível em: https://skin.dermsquared.com/skin/article/view/2417. Acesso em: 3 jul. 2025.